<DOC>
	<DOC>NCT02222922</DOC>
	<brief_summary>To assess the safety and tolerability at increasing dose levels of PF-06647020 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.</brief_summary>
	<brief_title>A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Fluconazole</mesh_term>
	<criteria>Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for whom no standard therapy is available Performance Status of 0 or 1 Adequate bone marrow, kidney, and liver function Part 2 includes ovarian cancer, target expressing triple negative breast cancer and non small cell lung cancer patients OVCA pts must have progressed while receiving or within 6mos after completion of at least 4 cycles of platinumcontaining regimen. Prior line of therapy up to 3 regimens. OVCA pts excluded with any of the following: nonepithelial, inlcuding malignant mixed mullerian tumors, prior radiotherapy to pelvis/abdomen, pts with CA125 only disease, unresolved bowel obstruction, including subocclusive disease, related to underlying disdease and history of abdominal fistula, GI perforation or itraabdominal abscess. Brain metastases requiring steroids Drugdrug interaction includes advanced metastatic breast cancer, ovarian cancer, or non small cell lung cancer patients Major surgery, radiation therapy, or systemic anticancer therapy within 4 weeks of study treatment start Active and clinically significant bacterial, fungal, or viral infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>ADC</keyword>
	<keyword>PF-06647020</keyword>
	<keyword>solid tumors</keyword>
	<keyword>tumors</keyword>
	<keyword>neoplasm metastasis</keyword>
	<keyword>TNBC</keyword>
	<keyword>triple negative breast cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>non small cell lung cancer</keyword>
	<keyword>advanced metastatic breast cancer</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>OVCA</keyword>
</DOC>